anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
A liquid in an area of low pressure (vacuum) vaporizes and forms bubbles, which then collapse as they enter high pressure areas. This causes liquid to fill the cavities left by the bubbles with tremendous localized force, eroding any adjacent solid surface.
== Substrate specificity == The phytaspase displays a strict substrate specificity, which resembles that of the animal caspase-3. It recognizes a tetrapetide motive within a target protein and introduces a peptide bond break following an aspartate residue, which is crucial for the hydrolysis. Theoretical speculations, based on a 3D model predictions have been made, pointing to the histidine 331 of the phytaspase peptide chain, that might interact with the Asp in the target peptide and thereby guide the recognition.
Vaccination campaigns began in Porto Alegre on 20 January 2021. Starting in January, the municipal government began to not keep second doses of the vaccine, immediately using up all of the supplies that they received from the Programa Nacional de Imunizações (PNI). This created delays in second doses by the end of April and the beginning of May, when there was a further delay in the sending out of doses of CoronaVac throughout Brazil. Long lines formed as a result of people waiting for the vaccine, but there were not enough doses to go around, implying that there were people who were immunized during a period longer than the four weeks recommended by the manufacturers. Melo recorded a video, which was released on social media, apologizing to the populace for the delays and claiming that the Ministry of Health was responsible for the error. Upon receiving the supplies of the Pfizer/BioNTech vaccine, the municipal government decided to keep the shots to be able to give a second dose, to avoid the same issue that occurred with the CoronaVac vaccines. In March, the Consortium of the Association of Municipalities of the Porto Alegre Metropolitan Region (Granpal), integrated by Porto Alegre's city government, made a proposal to buy doses of the Sputnik V vaccine that would be meant for, by law, the PNI. The purchase, however, did not go forward.
Sources: en.wikipedia.org
Skin grafts have been shown to control the recurrence of the disease. Extracorporeal shock wave therapy (ESWT) has, in some cases, been reported to significantly reduce pain and improve walking ability in patients with plantar fibromatosis. Collagenase injection, FDA-approved for Dupuytren's contracture with favorable outcomes, showed no benefit in a reported case of plantar fibromatosis. Cryotherapy has also been reported as an effective treatment for Ledderhose disease, with an approximate 80% success rate and potentially lower recurrence than conventional surgery. Cortisone injections, such as triamcinolone, and clobetasol ointments have been shown to stall the progression of the disease temporarily, although the results are subjective and large-scale studies far from complete. Injections of superoxide dismutase have proven to be unsuccessful in curing the disease while radiotherapy has been used successfully on early-stage Ledderhose nodules. Topical verapamil is also used to treat plantar fibromatosis.
4-Chloromethcathinone (also known as 4-CMC and clephedrone) is a stimulant drug of the cathinone class that has been sold online as a designer drug. 4-CMC produces similar effects to mephedrone, and has been sold as an alternative in countries where mephedrone was scheduled. 4-CMC produces similar side effects to mephedrone, including: increased blood pressure, tachycardia, hyperthermia, and anxiety. Its chemical structure closely resembles para-chloromethamphetamine, raising concerns about its potential to readily induce cell death of serotonergic neurons. However, no neurotoxicity of this kind has been found to occur, but studies involving mice do indicate that it is neurotoxic through other mechanisms, similarly to other cathinones. 4-CMC is cytotoxic and induces oxidative stress, more so than 4-MMC. Moreover, β-keto substitution is thought to change cathinone structure activity relationships (SAR) and metabolism compared to amphetamines, leading to differences in pharmacology.
Counter-Strike: Global Offensive is the fourth release in the main, Valve-developed Counter-Strike series in 2012. Much like Counter-Strike: Source the game runs on the Source engine. It is available for Microsoft Windows, OS X, and Linux, as well as the Xbox 360 and PlayStation 3 consoles, and is backwards compatible on the Xbox One console.
=== A10AE Insulins and analogues for injection, long-acting === A10AE01 Insulin (human) A10AE02 Insulin (beef) A10AE03 Insulin (pork) A10AE04 Insulin glargine A10AE05 Insulin detemir A10AE06 Insulin degludec A10AE07 Insulin icodec A10AE30 Combinations A10AE54 Insulin glargine and lixisenatide A10AE56 Insulin degludec and liraglutide A10AE57 Insulin icodec and semaglutide
Sources: en.wikipedia.org
To the east and north of the rebuilt central city are a stretch of old neighbourhoods (Danton, Saint-Vincent, Graville, Massillon, etc.) which were spared the bombings of World War II. The buildings, usually in brick, dated to the 19th and the first half of the 20th centuries. The shops are concentrated along several major roads in the Rond-Point neighbourhood. During the 1990s and 2000s, these neighborhoods have seen major redevelopments, particularly in the context of an OPAH: improvement of habitat by rehabilitation or reconstruction, creation of public facilities, and revitalization of business. At the end of the 20th century and beginning of the 21st century, the area around the railway station has undergone a major transformation. As the station is the gateway to the city with the main avenues intersecting here. New buildings have sprung up (University of Le Havre, the conservatory, headquarters of the SPB (Provident Society Bank), and of CMA CGM, Novotel, Matmut, new CCI) some of which were designed by renowned architects. The bus station, certified NF since 2005, has been refurbished. North of the station, another construction project in place of the dilapidated island of Turgot-Magellan will be opened in 2013, including 12,500 m2 (135,000 sq ft) of office space and an eight-storey hotel, complete with shops on the ground-floor.
== Advantages == The B1H system has significant advantages over other methods that investigate protein–DNA interactions. Microarray-based readout of chromatin immunoprecipitation (ChIP-chip) for high-throughput binding-site determination relies on specific antibodies which may not always be available. Methods that rely on protein-binding microarrays also require additional protein purification steps that are not required in the B1H system. Furthermore, these microarray-based techniques are often prohibitive in terms of requiring special facilities and expertise to analyze the resulting data. SELEX, another system commonly used to identify the target nucleic acids for DNA-binding proteins, requires multiple rounds of selection. In contrast, the bacterial one-hybrid system requires just one round of in vitro selection and also offers a low-tech alternative to microarray-based technologies. Antibodies are not required for studying the interactions of DNA-binding proteins in the B1H system. A further advantage is that the B1H system works not only for monomeric proteins but also for proteins that bind DNA as complexes. The B1H system should be considered a specialized technique for studying DNA-protein interactions whereas the two-hybrid variations (B2H and Y2H) can assess both protein–protein and protein–DNA interactions. These two-hybrid systems are multi-purpose but are limited in terms of assaying only a single “prey” library.
=== Mitigation measures === Several strategies have been proposed as a way to protect people at the greatest risk of occupational exposure to PFAS, including exposure monitoring, regular blood testing, and the use of PFAS-free alternatives such as fluorine-free firefighting foam and plant-based ski wax.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.